Form 8-K - Current report:
SEC Accession No. 0001104659-25-007574
Filing Date
2025-01-30
Accepted
2025-01-30 16:05:26
Documents
13
Period of Report
2025-01-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm254924d1_8k.htm   iXBRL 8-K 23495
  Complete submission text file 0001104659-25-007574.txt   197974

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20250124.xsd EX-101.SCH 3018
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20250124_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20250124_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT tm254924d1_8k_htm.xml XML 3808
Mailing Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE BCM-A, MS: BCM251 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 25573669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)